These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15385689)

  • 1. Erectile dysfunction: evaluation and new treatment options.
    Carson CC
    Psychosom Med; 2004; 66(5):664-71. PubMed ID: 15385689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of erectile dysfunction.
    Heidelbaugh JJ
    Am Fam Physician; 2010 Feb; 81(3):305-12. PubMed ID: 20112889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on oral treatments for male erectile dysfunction.
    Kalsi JS; Kell PD
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):267-74. PubMed ID: 15096134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
    Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
    BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety of PDE5 inhibitors.
    Herschorn S
    Can J Urol; 2003 Feb; 10 Suppl 1():23-8. PubMed ID: 12625847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of erectile dysfunction in patients with Peyronie's disease using sildenafil citrate.
    Levine LA; Latchamsetty KC
    Int J Impot Res; 2002 Dec; 14(6):478-82. PubMed ID: 12494281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of erectile dysfunction.
    Dinsmore W
    Int J STD AIDS; 2004 Apr; 15(4):215-21. PubMed ID: 15075013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study.
    Lee J; Pommerville P; Brock G; Gagnon R; Mehta P; Krisdaphongs M; Chan M; Chan J; Dickson R
    BJU Int; 2006 Sep; 98(3):623-9. PubMed ID: 16925764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erectile dysfunction, discrepancy between high prevalence and low utilization of treatment options: results from the 'Cottbus Survey' with 10 000 men.
    May M; Gralla O; Knoll N; Fenske S; Spivak I; Rönnebeck C; Hoffmann M; Lenk S; Hoschke B
    BJU Int; 2007 Nov; 100(5):1110-5. PubMed ID: 17922788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials.
    Blonde L
    Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil.
    Gruenwald I; Shenfeld O; Chen J; Raviv G; Richter S; Cohen A; Vardi Y
    Eur Urol; 2006 Jul; 50(1):134-40. PubMed ID: 16527391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction.
    Dunn ME; Althof SE; Perelman MA
    Int J Impot Res; 2007; 19(2):119-23. PubMed ID: 16738695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging oral drugs for erectile dysfunction.
    Briganti A; Salonia A; Gallina A; Suardi N; Rigatti P; Montorsi F
    Expert Opin Emerg Drugs; 2004 May; 9(1):179-89. PubMed ID: 15155143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts in erectile dysfunction.
    Mulhall JP
    Am J Manag Care; 2000 Aug; 6(12 Suppl):S625-31. PubMed ID: 11183414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
    Axilrod AC
    Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical, multicentric, and open study to evaluate the efficacy of and tolerance to sildenafil in patients with erectile dysfunction].
    Palha AP; Gomes FA; Martins AS; Pimenta A; Neves J; Gonçalves R; Ramos L; Abrantes P; Canhão A; Santos G; Carvalho LF; Soares J; Lima E; Rosa G
    Acta Med Port; 2002; 15(4):249-56. PubMed ID: 12525018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.